Funder
Agency for Science, Technology and Research
Duke-NUS Medical School
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference50 articles.
1. Ramón y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020;98(2):161–77.
2. Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol. 2014;6(2):43–51.
3. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.
4. Wang C, Yang J, Luo H, Wang K, Wang Y, Xiao Z-X, et al. CancerTracer: a curated database for intrapatient tumor heterogeneity. Nucleic Acids Res. 2020;48(D1):D797–806.
5. Verma M. Personalized medicine and cancer. J Pers Med. 2012;2(1):1–14.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献